Related Experiment Video

Updated: Sep 10, 2026

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

Adriamycin and other anthracycline antibiotics under study in the United States

R S Benjamin

    Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
    |January 1, 1978
    PubMed

    Insights

    Adriamycin demonstrates broad antitumor activity, significantly impacting sarcoma, breast, and lung cancer therapies. Combination regimens like FAC and CHOP show promise, though dose compromise affects efficacy.

    Area of Science:

    • Medical Oncology
    • Pharmacology
    • Cancer Therapeutics

    Background:

    • Adriamycin (doxorubicin) is a cornerstone chemotherapy agent.
    • Its broad-spectrum antitumor activity has been widely recognized.

    Purpose of the Study:

    • To review the established role and impact of Adriamycin in various cancer treatments.
    • To highlight effective combination regimens and emerging analogs.

    Main Methods:

    • Literature review of Adriamycin's clinical applications.
    • Analysis of combination chemotherapy regimens and novel analogs.

    Main Results:

    • Adriamycin shows significant efficacy in sarcomas, with a steep dose-response curve.
    • The FAC regimen yields excellent results in breast cancer.
    • CHOP regimen is effective for diffuse histiocytic lymphomas.
    • Adriamycin is comparable to daunorubicin in leukemias; Rubidazone shows promise in AML.

    Conclusions:

    • Adriamycin remains a vital drug across multiple cancer types.
    • Optimizing Adriamycin dosage in combination therapy is crucial for efficacy.
    • New analogs and regimens like ROAP warrant further investigation.

    More Related Videos

    Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice08:57

    Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

    Published on: October 5, 2017

    Assay Development for High-Throughput Drug Screening Against Mycobacteria07:50

    Assay Development for High-Throughput Drug Screening Against Mycobacteria

    Published on: October 25, 2024

    Related Concept Videos

    Drugs that Destabilize Microtubules01:10

    Drugs that Destabilize Microtubules

    Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
    Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

    Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

    Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
    Anthelminthic Agents01:15

    Anthelminthic Agents

    Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
    Clinical Significance of Antibiotic Resistance01:25

    Clinical Significance of Antibiotic Resistance

    Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...